Studies find conventional antidepressants minimally effective, leading to research into psychedelics like psilocybin and LSD. However, skepticism remains due to limited data and lack of formal approval by national regulators.
Axsome Therapeutics introduces Auvelity, combining dextromethorphan with a hallucination-negating drug for depression treatment. FDA approved in 2022, challenging the necessity of tripping in psychedelic medicine.
[
add
]
[
|
|
...
]